The SELECT trial and subsequent renal subgroup analyses suggested that, in populations with both obesity and pre-existing cardiovascular disease, semaglutide not only reduced the risk of cardiovascular events but also slowed the decline of the estimated glomerular filtration rate (eGFR) ( As indications have expanded from diabetes to obesity, GLP-1RAs have increasingly entered routine care for women of reproductive age, including those with PCOS, in whom obesity and insulin resistance are highly prevalent ( 1.4 Rationalizing fertility-centered review of GLP-1RAs in PCOS: bridging metabolic-reproductive divide 1.4.1 Clinical paradox: tension between metabolic optimization and reproductive urgency While GLP-1RAs have been established as a first-line intervention for managing metabolic comorbidities in PCOS, their potential teratogenic risks and the requirement for strict preconception washout periods present a formidable clinical dilemma for reproductive specialists
Advancements In GLP-1 Agonist Therapies For Diabetes And Weight Management GLP-1 agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists mimic naturally occurring incretin hormones to slow gastric emptying, increase the feeling of fullness, promote insulin secretion, and inhibit the inappropriate release of glucagon
When peptides are exposed to temperatures above their recommended storage range, the amino acid chains begin to unfold
GLP-1 receptor agonists shift macrophage polarization toward the M2 phenotype
Furthermore, GLP-1RAs have been associated with prevention of cardiovascular and kidney disease in diabetic population, which is ever more important in diabetic patients affected by SARS-CoV-2 [13]
This new avenue has yet to see a standout success, with Orforglipron emerging as a leading contender, showing promising results in blood sugar control and weight management according to clinical trials [14][15]
